Cardiovascular events are a major cause of death in patients with rheumatoid arthritis (RA). Recent data suggest that TNF inhibition can reduce both disease activity and the risk of acute coronary syndrome, adding to our knowledge of how RA therapies modify cardiovascular risk.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Widdifield, J. et al. Trends in excess mortality among patients with rheumatoid arthritis in Ontario, Canada. Arthritis Care Res. (Hoboken) 67, 1047–1053 (2015).
del Rincón, I. D., Williams, K., Stern, M. P., Freeman, G. L. & Escalante, A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum. 44, 2737–2745 (2001).
Roubille, C. et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann. Rheum. Dis. 74, 480–489 (2015).
Ljung, L. et al. Response to biological treatment and subsequent risk of coronary events in rheumatoid arthritis. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis-2015-208995 (2016).
Choy, E., Ganeshalingam, K., Semb, A. G., Szekanecz, Z. & Nurmohamed, M. Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment. Rheumatology (Oxford) 53, 2143–2154 (2014).
Ljung, L. et al. Treatment with tumor necrosis factor inhibitors and the risk of acute coronary syndromes in early rheumatoid arthritis. Arthritis Rheum. 64, 42–52 (2012).
Hitchon, C. et al. Self-reported comorbidity is common in early inflammatory arthritis and associated with poorer function and worse arthritis disease outcomes: results from the Canadian early arthritis cohort. Rheumatology (Oxford) (in the press).
Solomon, D. H. et al. Patterns of cardiovascular risk in rheumatoid arthritis. Ann. Rheum. Dis. 65, 1608–1612 (2006).
Pope, J., Keystone, E., Haraoui, B., Thorne, J. C. & Poulin-Costello, M. Number of cardiovascular risk factors may be associated with higher disease activity severity, exploratory analysis of baseline data from the Canadian Methotrexate and Etanercept Outcome Study: a randomized trial of etanercept and methotrexate versus etanercept alone in rheumatoid arthritis. Arthritis Rheum. 63, S488 (2011).
Joseph, R. M., Movahedi, M., Dixon, W. G. & Symmons, D. P. M. Smoking-related mortality in patients with early rheumatoid arthritis — a retrospective cohort study using the Clinical Practice Research Datalink. Arthritis Care Res. (Hoboken) http://dx.doi.org/10.1002/acr.22882 (2016).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
J.E.P. has no direct conflicts of interest but is involved in research studies and/or is consulting for AbbVie, Amgen, BMS, Celgene, GSK, Hospira, Lilly, Novartis, Pfizer, Roche, Sanofi and UBC.
Rights and permissions
About this article
Cite this article
Pope, J. TNF inhibitors and cardiovascular risk management in RA. Nat Rev Rheumatol 12, 317–318 (2016). https://doi.org/10.1038/nrrheum.2016.67
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2016.67
This article is cited by
-
Aortic aneurysm associated with rheumatoid arthritis: a population-based cross-sectional study
Clinical Rheumatology (2016)
